StockData
Incyte Corp logo

Incyte Corp (INCY) shareholders

INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3091% above fair value
$119.09−1.18 (-0.98%)

Close on Nov 17, 2026Market cap $24.27BP/E 63.3Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
99.4%
203M of 204M shares
Institutional holders
858
125 new, 71 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 53 sales
Net sold $67.37M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Felix J. Baker
Joint filing with Julian C. Baker (15.60%), Baker Bros. Advisors LP (15.40%) and 1 more
31,225,57215.60%13D (active) amendmentMay 7, 2026
BlackRock, Inc.15,242,1717.80%13G (passive) amendmentSep 30, 2025
Vanguard Capital Management12,591,6306.32%13G (passive)Mar 31, 2026
Dodge & Cox12,252,3566.20%13G (passive) amendmentMar 31, 2026
State Street Corporation9,677,4145.00%13G (passive)Sep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of INCYValueChange% of portfolio
Baker Bros. Advisors LP30,762,33015.09%$3.49B+17,91817.48%
BlackRock, Inc.18,032,7188.85%$2.04B−945,4800.03%
Dodge & Cox11,957,3265.87%$1.36B−295,0300.71%
Vanguard Capital Management LLC11,024,2895.41%$1.25B+94,2230.03%
State Street Corp9,722,3364.77%$1.10B+80,9520.03%
Vanguard Portfolio Management LLC7,791,0913.82%$883.20M+31,9080.04%
Aqr Capital Management LLC5,320,9012.61%$603.18M−487,0290.21%
Geode Capital Management, LLC4,750,7352.33%$536.52M+47,5510.03%
Lsv Asset Management4,123,7592.02%$467.47M+203,7030.85%
Invesco Ltd.4,080,4612.00%$462.56M+209,6970.04%
Wellington Management Group Llp3,575,5211.75%$405.32M+309,3850.07%
Renaissance Technologies LLC3,512,1321.72%$398.14M−139,4000.55%
Morgan Stanley2,948,3641.45%$334.23M+98,0360.02%
Arrowstreet Capital, Limited Partnership2,744,9581.35%$311.17M−85,8410.14%
Robeco Institutional Asset Management B.V.2,441,7351.20%$276.80M−72,6480.34%
Goldman Sachs Group Inc2,305,7821.13%$261.38M−45,4390.02%
Dimensional Fund Advisors LP2,280,8031.12%$258.59M+305,2590.05%
Two Sigma Investments, LP2,003,5590.98%$227.12M+1,587,6450.16%
Northern Trust Corp1,761,9660.86%$199.74M−87,7600.02%
Charles Schwab Investment Management Inc1,692,4390.83%$191.85M−36,6630.03%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026858203M99.4%125 / 363272 / 7111M12M
Q1 2026815204M100.0%109 / 320289 / 10435M12M
Q4 2025822202M98.9%175 / 336234 / 4918M13M
Q3 2025713199M97.6%126 / 264234 / 6317M15M
Q2 2025658197M96.7%101 / 263235 / 6319M11M
Q1 2025628190M93.2%73 / 258222 / 8319M11M
Q4 2024650183M89.9%125 / 243213 / 5715M16M
Q3 2024593184M90.5%83 / 171263 / 6930M22M
Q2 2024584198M97.3%73 / 226221 / 6819M44M
Q1 2024586224M100.0%88 / 216203 / 5215M13M
Q4 2023557223M100.0%98 / 197197 / 6124M14M
Q3 2023529212M100.0%51 / 249164 / 4718M13M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

774 funds held INCY in Q2 2026, 58% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of INCYValue% of fundAs of
Dodge & Cox Stock Fund7,953,1283.90%$901.57M0.76%Jun 30, 2026
Vanguard Total Stock Market Index Fund5,390,9222.64%$611.11M0.03%Jun 30, 2026
Vanguard 500 Index Fund4,346,9272.13%$492.77M0.03%Jun 30, 2026
Vanguard Small-Cap Index Fund3,894,3191.91%$441.46M0.23%Jun 30, 2026
Vanguard Health Care Fund2,386,2011.17%$285.20M0.75%Jul 31, 2026
iShares Core S&P 500 ETF2,309,8101.13%$261.84M0.03%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund2,245,6411.10%$254.57M0.54%Jun 30, 2026
Fidelity 500 Index Fund2,139,3081.05%$206.96M0.02%May 31, 2026
Invesco S&P 500 Equal Weight ETF1,767,8860.87%$211.30M0.22%Jul 31, 2026
iShares Biotechnology ETF1,402,6290.69%$159.00M1.75%Jun 30, 2026
VictoryShares Free Cash Flow ETF1,191,7860.58%$135.10M1.74%Jun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF1,185,5380.58%$134.39M0.33%Jun 30, 2026
Dodge & Cox Balanced Fund1,126,6000.55%$127.71M0.87%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF944,9220.46%$107.12M1.00%Jun 30, 2026
Vanguard Institutional Index Fund910,4230.45%$103.21M0.03%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
William MeuryChief Executive Officer, Director183,1290.09%Jul 20, 2026
Lee HeesonEVP, Head of Incyte Intl26,8840.01%Nov 17, 2026
Steven H. SteinCMO & Head of Late-Stage Dev.30,9160.02%Nov 10, 2026
Thomas TrayPrincipal Accounting Officer22,5250.01%Nov 5, 2026
Pablo J. CagnoniPresident, Global Head of R&D183,2000.09%Oct 19, 2026
David H. GardnerEVP, Chief Strategy Officer15,9040.01%Sep 24, 2026
Ramitpal K. BasiEVP, Human Resources10,9930.01%Aug 27, 2026
Patrick A. MayesEVP & Chief Scientific Officer63,6480.03%Aug 7, 2026
Michael James MorrisseyEVP, Head of Tech. Operations34,0650.02%Jul 27, 2026
Richard A. HoffmanEVP & General Counsel16,8610.01%Jul 20, 2026
Mohamed Khairie IssaEVP, Head of U.S. Commercial63,9400.03%Jul 20, 2026
Suketu UpadhyayEVP & Chief Financial Officer26,3430.01%May 6, 2026
Matteo TrottaEVP, GM, Dermatology US14,8820.01%Mar 26, 2026
Sheila A. DentonEVP & General Counsel26,5690.01%Nov 19, 2025
Vijay K. IyengarEVP, GMAPPS40,5400.02%Jul 17, 2025
Barry P. FlannellyEVP & General Manager US35,1490.02%Jul 17, 2025
Paula J. SwainEVP, Human Resources106,4820.05%Jul 16, 2025
Christiana StamoulisEVP & Chief Financial Officer125,7590.06%Jul 16, 2025
Edmund HarriganDirector23,2250.01%Oct 2, 2026
Bros. Advisors (GP) LLC BakerDirector, 10% owner28,497,74213.98%Oct 2, 2026
Bros. Advisors Lp BakerDirector, 10% owner28,487,27213.98%Oct 2, 2026
667, L.P.Director, 10% owner3,132,6391.54%Oct 2, 2026
Brothers Life Sciences LP BakerDirector, 10% owner28,502,18113.98%Oct 2, 2026
Felix BakerDirector, 10% owner28,517,94313.99%Oct 2, 2026
Julian BakerDirector, 10% owner33,757,52616.56%Oct 2, 2026
Paul J. ClancyDirector25,8380.01%Oct 2, 2026
Jacqualyn A. FouseDirector20,9680.01%Jun 10, 2026
Jean Jacques BienaimeDirector24,4240.01%Jun 10, 2026
Katherine A. HighDirector14,9830.01%Jun 10, 2026
Otis W. BrawleyDirector12,8940.01%Jun 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Lee Heeson
EVP, Head of Incyte Intl
Nov 13, 2026Sale(10b5-1 plan)−2,449$121.13$296.65K26,884
Lee Heeson
EVP, Head of Incyte Intl
Nov 13, 2026Sale(10b5-1 plan)−3,700$120.33$445.22K29,333
Lee Heeson
EVP, Head of Incyte Intl
Nov 13, 2026Sale(10b5-1 plan)−874$121.16$105.90K33,033
Lee Heeson
EVP, Head of Incyte Intl
Nov 13, 2026Sale(10b5-1 plan)−2,200$120.44$264.96K33,907
Lee Heeson
EVP, Head of Incyte Intl
Nov 13, 2026Sale(10b5-1 plan)−1,471$121.89$179.30K36,107
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Sale(10b5-1 plan)−48,576$119.66$5.81M30,916
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Sale(10b5-1 plan)−73,969$119.12$8.81M79,492
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Sale(10b5-1 plan)−60,270$118.27$7.13M153,461
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Sale(10b5-1 plan)−22,336$117.14$2.62M213,731
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Sale(10b5-1 plan)−35,042$116.06$4.07M236,067
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+19,091$113.64$2.17M271,109
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+17,986$113.64$2.04M252,018
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+879$113.64$99.89K234,032
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+24,838$83.20$2.07M233,153
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+15,054$83.58$1.26M208,315
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+12,743$90.56$1.15M193,261
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+16,428$85.01$1.40M180,518
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+6,907$68.25$471.40K164,090
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+12,305$64.25$790.60K157,183
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+19,749$61.18$1.21M144,878
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+18,331$61.76$1.13M125,129
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+23,526$77.67$1.83M106,798
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+15,054$74.78$1.13M83,272
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+16,428$80.50$1.32M68,218
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+12,335$72.27$891.45K51,790
Steven H. Stein
CMO & Head of Late-Stage Dev.
Nov 6, 2026Option exercise+8,539$68.62$585.95K39,455
Thomas Tray
Principal Accounting Officer
Nov 3, 2026Sale(10b5-1 plan)−610$118.96$72.57K21,126
Pablo J. Cagnoni
President, Global Head of R&D
Oct 15, 2026Sale(10b5-1 plan)−2,642$112.71$297.78K183,200
Pablo J. Cagnoni
President, Global Head of R&D
Oct 15, 2026Option exercise+925$64.25$59.43K185,842
Pablo J. Cagnoni
President, Global Head of R&D
Oct 15, 2026Option exercise+455$61.18$27.84K184,917
Pablo J. Cagnoni
President, Global Head of R&D
Oct 15, 2026Option exercise+423$61.76$26.12K184,462
Pablo J. Cagnoni
President, Global Head of R&D
Oct 15, 2026Option exercise+839$71.93$60.35K184,039
Lee Heeson
EVP, Head of Incyte Intl
Oct 1, 2026Tax withholding−463$117.14$54.24K37,578
Paul J. Clancy
Director
Sep 30, 2026Award+203$121.35$24.63K25,838
Bros. Advisors Lp Baker
Director, 10% owner
Sep 30, 2026Award+322––28,206,082
Bros. Advisors Lp Baker
Director, 10% owner
Sep 30, 2026Award+322––2,835,403
Edmund Harrigan
Director
Sep 30, 2026Award+206$121.35$25.00K23,225
David H. Gardner
EVP, Chief Strategy Officer
Sep 22, 2026Tax withholding−920$126.93$116.78K15,904
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Option exercise+2,957$61.76$182.62K186,157
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Option exercise+4,551$61.18$278.43K190,708
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Option exercise+6,477$64.25$416.15K197,185
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Option exercise+9,233$71.93$664.13K206,418
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Sale(10b5-1 plan)−13,985$120.49$1.69M183,200
Pablo J. Cagnoni
President, Global Head of R&D
Sep 15, 2026Sale(10b5-1 plan)−9,233$120.50$1.11M197,185
Ramitpal K. Basi
EVP, Human Resources
Aug 25, 2026Tax withholding−504$129.72$65.38K10,993
Pablo J. Cagnoni
President, Global Head of R&D
Aug 19, 2026Sale(10b5-1 plan)−10,801$125.56$1.36M183,200
Pablo J. Cagnoni
President, Global Head of R&D
Aug 12, 2026Sale(10b5-1 plan)−10,803$120.04$1.30M194,001
Pablo J. Cagnoni
President, Global Head of R&D
Aug 5, 2026Sale(10b5-1 plan)−10,640$122.69$1.31M204,804
Patrick A. Mayes
EVP & Chief Scientific Officer
Aug 5, 2026Option exercise+2,207$106.47$234.98K63,648
Patrick A. Mayes
EVP & Chief Scientific Officer
Aug 5, 2026Sale(10b5-1 plan)−2,207$123.99$273.65K61,441
Patrick A. Mayes
EVP & Chief Scientific Officer
Aug 3, 2026Sale(10b5-1 plan)−6,055$120.43$729.20K61,441
Patrick A. Mayes
EVP & Chief Scientific Officer
Aug 3, 2026Option exercise+6,055$105.43$638.38K67,496
Pablo J. Cagnoni
President, Global Head of R&D
Jul 31, 2026Sale(10b5-1 plan)−15,888$119.70$1.90M215,444
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Option exercise+3,148$68.62$216.02K74,687
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Option exercise+2,709$61.76$167.31K71,539
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Option exercise+2,284$64.25$146.75K68,830
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Option exercise+2,918$61.18$178.52K66,546
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Sale(10b5-1 plan)−2,293$119.41$273.81K61,441
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Sale(10b5-1 plan)−326$121.69$39.67K63,734
Patrick A. Mayes
EVP & Chief Scientific Officer
Jul 31, 2026Sale(10b5-1 plan)−85$122.19$10.39K64,060

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.82%
11M shares short
Days to cover
5.6
At 2M shares a day
Change since last report
+6.2%
From 10M shares
Short volume, 20 days
69.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Incyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,688 shares on Sep 8, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Steven H. Stein
Officer
Nov 6, 2026240,193$28.35MNov 6, 2026Exercise of Stock Options
Thomas Tray
Officer
Nov 3, 2026610$73.22KNov 3, 2026Employee Stock Purchase Plan
Pablo J. Cagnoni
Officer
Oct 15, 20262,642$297.78KOct 15, 2026Stock Option Exercise
Pablo J. Cagnoni
Officer
Sep 15, 202623,218$2.80MSep 15, 2026Stock Option Exercise
Pablo J. Cagnoni
Officer
Aug 19, 202610,801$1.36MAug 19, 2026Restricted Stock and Performance Shares
Pablo J. Cagnoni
Officer
Aug 12, 202610,803$1.30MAug 12, 2026Performance and Restricted Stock
Pablo J. Cagnoni
Officer
Aug 5, 202610,640$1.31MAug 5, 2026Restricted Stock and Performance Shares
Patrick A. Mayes
Officer
Aug 5, 20262,207$273.65KAug 5, 2026Stock Option Exercise
Patrick A. Mayes
Officer
Aug 3, 20266,055$729.20KAug 3, 2026Stock Option Exercise
Patrick A. Mayes
Officer
Jul 31, 202641,899$5.01MJul 31, 2026Stock Option Exercise
Pablo J. Cagnoni
Officer
Jul 31, 202615,888$1.90MJul 31, 2026Restricted Stock
Mohamed Khairie Issa
Officer
Jul 16, 20261,093$125.71KJul 16, 2026Restricted Stock
Steven H. Stein
Officer
Jul 16, 20261,877$215.34KJul 16, 2026Restricted Stock
Steven H. Stein
Officer
Jul 15, 202628,237$3.19MJul 15, 2026Performance Shares
Thomas Tray
Officer
Jun 4, 20262,639$263.90KJun 4, 2026Stock Option Exercise

Congress trades

5 trades in Incyte reported by 4 members of the House

MemberTypeTradedAmountFiled
Rob Bresnahan
PA08
SoldMay 15, 2025$1K–15KMay 31, 2025
Daniel Goldman
NY10
SoldMar 6, 2023$1K–15KApr 17, 2023
Gilbert Cisneros
CA31
SoldDec 22, 2020$1K–15KJan 11, 2021
Gilbert Cisneros
CA31
BoughtSep 16, 2020$1K–15KOct 14, 2020
Ed Whitfield
KY01
BoughtSep 22, 2014$1K–15KOct 8, 2014

See a number that looks wrong?